Enzolytics Inc (ENZC)

[MAGA_PATRIOT]

Daily Reminder for those who need it....

ENZC closed at .1162 on January 12th, 2021. So..... Are we to believe that we are legitimately worth 42% less, after all of this? LOL...... You really can't make this stuff up!

1.19.2021 - Official Filing Receipt for the MS Patent Application

2.1.2021 - Discovery of 7 Newly Identified Conserved Target Sites of the HIV Virus

2.9.2021 - Study of the Antiviral Effect of IPF on the replication of human coronavirus strain 229E (HCoV-229E)

2.16.2021 - Announced In-Vitro Test Results for ITV-1 Against HCoV-229E

2.22.2021 - Discovery of 11 Newly Identified Conserved Target Sites of the SARS-CoV-2

2.22.2021 - Formation of International Medical Partners (IMBL), a Bulgarian LLC

3.8.2021 - Discovery & Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus

3.16.2021 - Distribution and Operational Agreement for ITV-1 with IMBL

3.18.2021 - Filing of Provisional Patent for Monoclonal Antibodies

3.22.2021 - Filing of Updated NIH Grant Application to Include Newly ID’d Conserved Sites

4.5.2021 - Coronavirus Targeted Epitopes Claimed in Pending Patents are Verified as Fully Conserved

4.14.2021 - Presentation of Technology on the Emerging Growth Conference

4.19.2021 - Updates on Multiple Therapeutics’ Platforms and Initiatives

5.11.2021 - Enzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Company's Strategic Communication Firm

5.12.2021 - Granted a Distributorship License to Rosetta Lifecare Bulgaria to Distribute ITV-1 in Designated Areas

5.17.2021 - Enzolytics & Intel Co-Author White Paper on use of AI

5.26.2021 - Announced the Discovery of Conserved, Immutable Sites on HTLV-1 & Plans to Produce mAbs Targeting Sites

6.7.2021 - Updates on Therapeutic Protocol to Produce mAbs to Address Ongoing & Future Pandemics

6.14.2021 - Updates on Completion of Clinical Trials for ITV-1 & Plans for Distribution throughout Europe

6.20.2021 - Announced the Signing of LOI w/ Creative Biolabs, Inc. for Licensing & Commercialization of anti-HTLV-1 mAbs

6.22.2021 - Site Visit of VetProm Facilities for Production of ITV-1 for Clinical Studies

7.26.2021 - Appointment of Steve Sharabura as President of RobustoMed

7.27.2021 - COO, Dr. Gaurav Chandra Featured on C&EN Discovery Report

7.29.2021 - Agreements with Danhson and Clinic Design to Advance ITV-1 to Production & Clinical Trials

8.25.2021 - Updates on the Production of Anti-Coronavirus mAbs & the Production / Clinical Trials of ITV-1

8.30.2021 - Study of the Antiviral Effect of IPF on the Replication of Human Herpes Simplex Virus

9.18.2021 - Updates on Two Therapy Platforms for Treating HIV

10.7.2021 - Enzolytics Inc. and Samsung Biologics Announce CDMO for Anti-HIV and Anti-SARS-CoV-2 mAbs

10.13.2021 - Study of the Cytotoxic Effect of IPF on Cell Cultures

11.8.2021 - Announced Program for Creation of Animal mAbs Using Hybridoma & Phage Display Tech

11.12.2021 - RobustoMed Received Initial Funding to Market Products in Central & Latin America

11.17.2021 - Announced Production & Sale in North America of Enzolytics IPF Immune

11.19.2021 - Topographic Study of Cells Infected w/ HCoV-229E/HSV-1 & Treated w/ IPF

12.1.2021 - Yuan Article “Demystifying the Human Microbiome Using AI” by COO, Dr. Gaurav Chandra

12.2.2021 - Enzolytics Announces Progress As It Recognizes World AIDS Day